Combined targeting of CD33 and CLL-1 could offer a valuable strategy against heterogenous disease as both antigens are often upregulated on AML, although complete expression of either may not be complete across entire blast populations to enable monotherapy approaches. Here, CD33 is linked to acute myeloid leukemia.